DEV Community: Priya Nair

Automation bias is a risk control — treat your UI like a safety device

Priya Nair — Tue, 18 Aug 2026 09:42:58 +0000

I started noticing the same pattern in our usability tests: a confident suggestion on screen, a tired clinician at 03:00, and a near-miss that never made it into the incident log because everyone assumed "the machine is right". To be fair, the intention behind AI support is to reduce errors — granted — but if your UI is designed so the clinician cannot reasonably question or override the AI, that design choice is itself a risk control (and a brittle one).

This is not academic. IEC 62366-1 (usability engineering) expects manufacturers to identify use-related hazards and verify that the user interface mitigates them. The EU AI Act (Article 14) requires appropriate human oversight measures for high‑risk systems. ISO 14971 asks us to treat use-related hazards like any other hazard. In practice this means automation bias — users deferring to automated suggestions — should be in your risk analysis, your usability report, and your human‑oversight strategy in the Technical File.

What automation bias looks like in the wild

I've seen it in three recurring flavours:

Silent confidence: the UI shows a single recommended action without uncertainty or provenance. Clinician accepts without checking data.
Frictionless override buried: an override exists but is tucked behind multiple clicks; in an emergency people default to the path of least resistance.
Audit blindness: the system logs the AI action but not the human override rationale, so post‑market surveillance cannot reconstruct why someone overrode or didn't.

Each is a design decision with regulatory consequences.

Why this is regulatory, not just UX

IEC 62366‑1: you must identify use‑related hazards and mitigate them through design and verification. If your UI increases the likelihood of an incorrect action because users over‑trust the AI, that's a use‑related hazard and will be a usability finding.
ISO 14971: automation bias is a foreseeable source of harm; it needs classification, risk estimation, and documented risk control measures. You cannot just write "train users" as the only control and call it a day.
EU AI Act, Article 14: for high‑risk AI, you must implement human oversight measures that reduce risks linked to automation bias (e.g., ensure the human can understand and reasonably contest the AI output). The AI Act does not leave "human oversight" vague.

Notified bodies are increasingly flagging both IEC 62366 non-conformities and weak human oversight measures in AI‑assisted devices. In audits I've run, a lack of active push‑back mechanisms in the UI was the single most common finding.

Practical risk controls that actually work

In my teams we moved from "UX is pretty" to "UX is a safety subsystem". Here are controls that became standard in our technical files and usability reports:

Explicit uncertainty and provenance
- Show confidence bands, key inputs, and the most recent data timestamp. If the user cannot see these fast, they tend to accept the output.
Reduce passive acceptance
- Require an explicit, deliberate confirmation for high‑risk recommendations (not a single tap). In practice this means a two-step confirm or a short forced pause for critical actions.
Make override immediate and low-friction
- Place the override next to the recommendation. Log the override and capture a short, structured rationale (predefined options + optional free text).
Scenario-based verification
- Run summative usability tests under realistic cognitive load (interruptions, fatigue, incomplete data). Measure reliance and record near-misses.
Traceable human oversight strategy
- Include a documented human‑oversight concept in the Technical File: who may override, when, what training is required, and how overrides are logged and reviewed.
Post‑market monitoring for automation bias
- Add specific PMCF questions and PSUR signals that look for patterns of over‑reliance or frequent overrides without rationale.

How to show this to a notified body

Bring evidence, not assertions. Auditors want to see:

The hazard analysis with automation bias explicitly listed (ISO 14971)
Usability tests that mimic real-world distractions and quantify over‑reliance (IEC 62366‑1)
The human oversight strategy mapped to the AI Act Article 14 elements: operator competences, HMI design, and logging/auditability
Traceability: from hazard → risk control → verification method → test results → change control tickets

In practice this means traceability matrices need to be living artifacts, not dead Word tables. Use your eQMS so CAPAs, changes and verification evidence are linked and reviewable.

Where teams trip up

"Train them better" as a solo control. Training helps, but it's not a design control. It’s compensatory and must be combined with interface and system controls.
Hiding uncertainty because it "confuses clinicians". This choice shifts the burden onto the user and increases risk.
Expecting clinical governance alone to catch it. If the UI invites blind trust, the clinician will accept it under workload.

Quick checklist you can use today

Is automation bias listed in your ISO 14971 risk analysis? (If not, add it.)
Does your summative usability test include time pressure and interruptions?
Can the clinician override without friction and is the override logged with rationale?
Do your logs capture AI inputs, AI output confidence, timestamp and the human response?
Is there a defined human‑oversight strategy in the Technical File linked to verification evidence?

Final note

This is not about demonising AI; it's about recognising that when you put a suggestion in front of a human, you've created a small socio‑technical system. The interface is not neutral — it is a safety device. Treat it with the same rigour you treat hardware interlocks.

How have you designed a UI to reduce automation bias in your device, and what evidence did your notified body find convincing?

If “Can we ship tomorrow?” takes three days of digging, your release process is the problem

Priya Nair — Mon, 17 Aug 2026 15:15:00 +0000

I get this question every few months: "Can we ship tomorrow?" Usually it's asked with a sales deadline, a customer promise, or a production line breathing down everyone’s neck. My honest answer is almost always the one people do not want to hear: not until I spend three days checking five different systems.

To be fair, the question is reasonable. Leadership wants a single, reliable yes/no. The problem is that at too many small and mid‑size medtech firms that single number is not a single data point — it's a scavenger hunt.

What I actually have to check (and why it’s slow)

A compliant release isn't just "has the box been packed". In practice this means confirming a handful of gating items that live in different places:

Design verification/validation artefacts (PLM or shared drive)
Risk status and outstanding mitigation actions (risk register, sometimes a spreadsheet)
Change control state affecting the batch or lot (eQMS change module or emails)
Supplier nonconformances and material certificates (ERP / supplier portal)
Batch records, test reports and the Device History Record (manufacturing system / lab LIMS)
Regulatory status: CE certificate validity, notified body open actions, and EUDAMED/registration details

Each of those is a legitimate regulatory concern. Annex II of the MDR requires a complete technical file and traceability between design, risk and verification. The notified body will ask for the same things during audits. The trouble is, every one of those records can be in a different system and – worse – be represented differently.

Why this is a process problem, not an IT problem

People often propose "put everything in one system" as the panacea. Granted, single‑vendor solutions can help, but the root cause is operational:

Missing release criteria: nobody has clearly documented what “ship” means for each device and each regulator.
Data without links: the risk register references a change control number that lives only on a PDF; test reports reference a drawing revision that isn’t tagged in PLM.
No release owner: there is no single accountable person who can say "I confirm these five things".
Manual, brittle workflows: document reviews, CAPAs and supplier clears are often ad hoc emails or spreadsheets.

Those lead to the three‑day digging exercise. It’s not that the data doesn’t exist; it’s that it isn’t connected, reviewable and traceable at the moment of decision.

What to do when leadership asks “now” — a practical triage

You cannot conjure the perfect system overnight. You can, however stop lying and give leadership a reliable, actionable answer.

Step 1 — short, honest status in 10 minutes:

"I cannot approve shipment right now. I need X hours to confirm items A, B and C. The likely blockers are supplier certificates and the pending change control."

Step 2 — a 3‑point, 72‑hour plan (what I actually do):

Hour 0–4: Confirm owner and assign responsibilities for each gate (DHR, risk, change, supplier).
Day 1: Pull the most recent test reports and the batch record; validate signatures and revision numbers.
Day 2: Reconcile change control and supplier certificates; escalate any deviations as a hold and open CAPA if needed.
Day 3: Final review and issue release or formal hold.

Step 3 — keep leadership informed with one canonical status update at the end of each workday.

This is not heroic. It’s disciplined. It also makes the decision auditable later.

Fixes that stop the three‑day scramble — practical, not theoretical

If you want to push the organisation to a point where “can we ship tomorrow?” is a quick, accurate question, start with these concrete items:

Define release criteria per device and per regulatory market. Make these checklists official and bind them into change control and batch release workflows.
Assign a release owner role for each product line (not "QA desk"). That person is accountable for the single number.
Stop treating traceability matrices as static documents. Build living links between risk, design, verification and manufacturing records so a reviewer can follow the chain fast.
Integrate risk management into project management. When RM lives in the same lifecycle view as design and change control, you get traceable history — less detective work when a shipment decision is due.
Make the QMS usable: native workflow integration, connected workflow, and reviewability are what matters. Controlled assistance (e.g. AI‑assisted suggestions for CAPA categorisation) can help, but only where the decision path remains reviewable and auditable.
Validate the tooling you rely on. If your eQMS is a device for decisions, it should be validated per appropriate guidance (for example, ISO/TR 80002‑2 for QMS software validation) so you can trust the automation and outputs.

Low‑hanging wins are often cultural: a brief daily stand‑up with the release owner, a standardized release checklist, and a guaranteed 24–72 hour “can we ship” SLA.

Auditability and business outcomes

Fixing this is not purely about speed. It reduces audit stress, lowers the risk of non‑conforming shipments, and makes notified body interactions far less stressful. The day you can hand an auditor a single release record that traces back to the risk register and the DHR is the day you stop doing forensic work for routine releases.

To be fair, implementing these changes requires investment and discipline. But the cost of continuing to treat one number per device per regulator as a research project is paid in delays, customer dissatisfaction, and ultimately regulatory risk.

What’s the single data point in your company that takes the longest to verify before a shipment — and why does it still live in three different places?

If your QMS vendor says “AI” — ask them to name the model, the validation, and the human reviewer

Priya Nair — Mon, 17 Aug 2026 15:14:57 +0000

I started clicking through demos from “AI‑enabled QMS” vendors because our CAPA backlog was becoming a tragedy and the marketing looked like an aspirin for the whole team. The demos were slick. The slides used the right words: “machine learning”, “natural language”, “automated CAPAs”. But the moment I started asking operational questions, the glow faded. Antworten? Vague. Genau: if a vendor can’t name the model, show the validation, and explain the human‑in‑the‑loop, they’re selling a story, not compliance.

Below is what I now ask, in order, and why each point matters for an EU/US medtech firm operating under ISO 13485 and FDA expectations. In practice this means you can avoid deploying a “clever” tool that fails your next audit or, worse, creates undocumented decisions that affect patient safety.

What “AI‑powered” usually means in demos — and why that’s not enough

Vendors layer AI words over three different realities:

a simple search index with boosted keywords,
a rules engine wrapped in NLP to surface likely documents,
or an actual machine learning model that generates outputs and recommendations.

All three can be useful. The regulatory difference is whether the software is being used for documentation support, decision support, or automated decision‑making. FDA and ISO expectations hinge on the Intended Use — “for Intended Use” validation for FDA, and ISO 13485’s “for use” validation language (see ISO 13485, p.5). If the vendor won’t say which of the above they ship, you don’t know what you’re buying.

Name the model — versioning and provenance matter

Ask the vendor to name the model and version they are using. That includes:

model family and version (e.g., “transformer-based model X, v2.3”), or the exact search/indexing product if not an ML model,
whether it’s third‑party (SaaS vendor uses external LLM) or in-house,
update frequency and change control: how will you be notified of model upgrades?

Why: you must be able to tie a specific behaviour to a specific software version during audits or investigations. If an LLM update changed how the tool classifies nonconformities, you need traceability and evidence of risk re‑assessment.

Show the validation — test cases, pass/fail criteria, and traceable evidence

“Validated” is not a sticker. Validation for QMS software must align with intended use. Practical requests:

validation plan and protocol (test objectives, acceptance criteria),
representative test cases and test data sets (including edge cases),
traceable results showing pass/fail against acceptance criteria,
evidence of independent reviewer(s) and versioned validation artefacts,
supplier documentation you can include in your validation basis (per typical purchasing/validation guidance).

To be blunt: if validation is “we tested it internally” with no documented test plan or traceable outputs, it will not survive an audit. Get the artifacts before procurement.

Define the human in the loop — who, when, and how

AI outputs in a QMS are useful only if human decisions are reviewable and traceable. Ask:

what role is expected to review AI suggestions (engineer, RA, QA),
clear thresholds for escalation (confidence scores, types of classification that must be human‑confirmed),
how the human’s decision is captured and linked to the artefact (audit trail, signature, timestamp),
training material and competence expectations for reviewers,
how disagreements are logged and used to retrain or tune the model.

In practice this means the system should not be able to auto‑close a CAPA without an auditable human decision recorded. “Automated CAPAs” is a feature you should be sceptical of unless you have the documentation.

What else to check — security, data residency, and change control

AI introduces other vectors you must be able to manage:

data handling: where is your QMS data used for model training or inference? EU residency, DPAs, and supplier commitments matter,
logging and reproducibility: can you reproduce the exact output given the same input and model version?
change control & supplier change notifications: how are model updates handled in the supplier’s lifecycle and how will you reflect that in your QMS?

These are not optional. They feed into risk assessments, PSURs, and Potentially into your clinical evaluation if outputs interact with clinical decision making.

A short checklist I use before accepting an “AI” QMS feature

Vendor names the model and version, and documents the update policy.
Vendor provides a validation plan, test cases, and results you can keep in your Technical File.
There is a documented human‑in‑the‑loop process with traceable review records.
Supplier provides the documentation you need to build your validation basis (yes — ask for it in the contract).
Change control and notification procedures for model updates are in the SLA.
Data residency and DPA terms are explicit for training and inference.

If any of these are missing, the pitch is marketing.

Why this matters to RA/QA teams

To be fair, AI can dramatically reduce time spent finding records, drafting CAPA text, or surfacing repeat complaints. I’ve seen good implementations speed up triage. Granted, if you can’t justify the tool in your validation and risk management records, the benefit evaporates under audit pressure. In the worst case, you create undocumented decisions that complicate corrective actions and vigilance reporting.

In practice this means your procurement and validation plan must require supplier artefacts up front. Don’t ask for “a demo” and sign a contract. Ask for the documents that let you validate the tool against your Intended Use.

What I want to know from you: what’s the most useful single item you ask a vendor about AI in a QMS before you’ll even consider a trial?

Ask your eQMS vendor this one question about the AI Act — and listen to the answer

Priya Nair — Fri, 14 Aug 2026 06:50:47 +0000

Ask any eQMS vendor today: "the AI Act transparency rules came into force on 2 August — what did you change, and can you show me?" How they answer tells you more about their product and mindset than any brochure ever will.

I asked that exact question across three demos last week. One vendor gave me a single, concrete sentence and then walked me through artefacts in ten minutes. The others danced around policy and roadmap promises. To be fair, the AI Act spans several obligations and implementation is not trivial — granted — but in practice this means an eQMS used by regulated device manufacturers must do two things well: produce the artefacts regulators expect, and reliably tie those artefacts into the rest of your QMS (risk, change control, supplier management, validation).

Why one sentence matters

If a vendor can answer succinctly, they are usually telling you:

They have implemented specific capabilities (not just a high-level plan).
They have thought through how AI documentation fits into regulated workflows.
They can show traceable outputs quickly in a demo environment.

If they deflect, waffle about "guidance evolving", or promise "we'll add a feature", they are telling you:

The feature is not materially available today, or
They see the AI Act as a product marketing opportunity rather than something that must integrate with your regulatory artefacts.

Genau — the difference is practical, not philosophical.

What the AI Act transparency obligations mean for a medtech eQMS

You do not need the vendor to be your regulatory consultant, but you do need the eQMS to support the documentation and traceability the Act expects. For a medical device manufacturer that already follows MDR 2017/745, these are the practical implications I expect to see supported:

Structured artefacts: model cards / system descriptions, documentation of intended use, and user-facing transparency statements that can be versioned and exported into the Technical File (Annex II relevance).
Provenance and datasets: records of training/validation datasets, who supplied them, and any preprocessing steps — linked to supplier management and data agreements.
Change & version control: model version history, release notes, and ability to link each model version to its risk assessment and validation evidence (IEC 62304 / ISO 14971 ties).
Audit trail & explainability logs: immutable logs that show how an inference engine was tested/validated and how decisions are explained for a given release.
Supplier/subcontractor evidence: contracts, subcontractor assessments, and evidence of AI component validation retained in one place.
User-facing disclosures: templated text for information to users/clinicians and a way to evidence when disclosures were deployed.
Post-market monitoring linkage: ability to correlate incidents, PSUR/PMCF data, and model performance drift with model versions and trigger CAPAs (automated CAPAs, preferably).

If your eQMS does not make these linkages easy, you will be stitching evidence together manually — slow, error-prone, and uncomfortable in a notified-body audit.

What a good one-sentence vendor answer looks like

A strong, credible one-liner is specific, not vague. Examples of the shape of a good answer (you can ask for this exact phrasing in a demo):

"We added an AI transparency module that produces model cards, stores dataset provenance, and links each model version to validation evidence, change control, and risk assessments — here's a demo record."
"We extended our Change Impact Mapping so model updates automatically populate the MDR-relevant Technical File annex and create a linked CAPA template when performance drift exceeds thresholds."
"We have a templated transparency statement that can be signed, versioned, and exported into your Technical File; it includes a model provenance report and a dataset manifest."

If a vendor says any of the above and then shows you a real record in the demo tenant, that is meaningful.

Concrete things to ask for in the demo (and what to expect)

Ask for these demonstrations. A vendor who can do each in five minutes is not selling smoke:

Show me a model card for a deployed model and the dataset provenance record that created it.
Show me the model version history and the linked validation evidence (test reports, IEC 62304 artefacts).
Trigger a simulated model update and show the change control workflow + automated risk assessment link.
Export the artefacts you would include in an Annex II Technical File export for a software update.
Show how post-market performance data is linked to model versions and how a CAPA is opened automatically.

Red flags during the demo:

No linked artefacts — everything is "in a PDF" or in separate systems.
"That's on our roadmap" without a target date or sandbox.
No immutable audit trail for model decisions and versioning.

Validation and QMS reality

Validation of software remains obligatory — you will still need documented software validation per your QMS and relevant standards. Expect to map the eQMS outputs into:

ISO 13485 process records,
IEC 62304 software lifecycle documentation,
ISO 14971 risk management outputs,
Your MDR Technical File (Annex II/III) and post-market files.

An eQMS that claims AI support but cannot demonstrate how it feeds validated artefacts into these outputs is not worth the powerpoint.

Final practical note

In regulated medtech, transparency obligations are not a marketing checkbox — they are traceability, and notified bodies will want to see the chain from model development to deployment to post-market monitoring. Your eQMS should make that chain discoverable and auditable, not just possible with heroic searches.

What did your current or prospective eQMS vendor say when you asked this question — and did they show it?

Article 50 landed — December 2 is the real deadline, not August

Priya Nair — Thu, 13 Aug 2026 12:56:22 +0000

I stopped worrying about August and started worrying about December the moment Article 50 actually slipped into application. To be blunt: every AI system we already had running has until 2 December to add the disclosure. "We’ll do it in Q4" is how you end up fixing this in week 48 with three devs answering Slack at 22:00 and the Clinical Safety Officer approving wording from a phone on the tram. Been there; trying to avoid repeating it.

Here’s how I’m running the work right now — practical, low-friction steps for a tight RA/QA team that has a lot else to deliver.

Immediate triage (day 0–3)

First, treat this like a regulated change to a device, because it is.

Inventory every product, subsystem and service that uses an AI component (on-device, cloud, inference pipelines, third-party APIs).
Mark which ones are in-market, which are in clinical use, which are in beta.
Assign an owner for each item (dev lead / product manager / RA) and create a single change ticket per product in your QMS. Traceability matters — link that ticket to the Technical File, risk assessment and IFU/label items.

In practice this means one central place where the disclosure work lives. If your eQMS doesn’t let you link change-to-Technical-File sections and risk items, you’ll pay for it in week 48.

What the work actually is (not just wording)

Adding a disclosure is not only a line of copy. Expect work in these areas:

UX: where and how the disclosure appears (splash screen, settings, before each session). Usability and readability matter.
Localisation: translations into EU languages used where you sell the device.
Logging: ensure the system records when users saw/acknowledged the disclosure.
Docs: update IFU, quick-start guides, online portals and the Technical File (Annex II).
Software change control: version bump, release notes, regression testing per IEC 62304 processes.
Risk assessment: update the risk management file (ISO 14971) for the disclosure’s impact (e.g., does the disclosure change intended use or operator decision-making?).
Post-market: update your PMS/PMCF plans and PSUR templates to capture any new incidents tied to the disclosure or behavioural changes.
Third parties: require vendors/APIs to provide their own disclosure evidence if they’re in your user flow.

If you try to treat the disclosure as “marketing copy” and drop it into a web banner at the last minute, you will fail the traceability and documentation checks in an audit.

Practical drafting and UX tips

I prefer a short, plain-language statement plus a link to more detail. Practically:

Keep the headline one line: "This system uses an AI component to [what it does]."
One follow-up sentence for limitations: "Outputs are probabilistic and should be reviewed by a qualified clinician."
A link: "More information (how it works, data sources, performance, contact) →"
Provide a way to replay or access the exact prompt or input used, where feasible, or explain why you cannot (privacy/cyber reasons).
Ensure the disclosure is visible at the correct user journey point — before the AI output influences a clinical decision.

Test the disclosure with a clinician early. They’ll tell you whether the wording is noise or actually helpful.

Schedule backwards from 2 December

Don’t wait for a single sprint. My timeline template:

Week 0–1: Inventory, owners, decision on UX location.
Week 1–2: Draft disclosure copy, language list, confirm legal/clinical sign-off owners.
Week 2–4: Implement UI changes, logging, translations.
Week 4–5: QA/regression testing, accessibility/usability checks.
Week 5–6: Release to production or staggered rollout; update Technical File and PMS artefacts.
Buffer: 1–2 weeks for hotfixes and notified-body communications if required.

That’s deliberately compact. If you’re already in dev cycles, you can overlap steps — but you must not skip linking the change to your Technical File and risk documents.

QMS and notified body considerations

From a QMS perspective, treat this as a controlled change:

Raise change control, update the Architecture and Software Description in the Technical File (Annex II).
Update your risk management (ISO 14971) and clinical evaluation if the AI output affects clinician decisions (Annex XIV touches on continuing evaluation).
If the disclosure or UI change affects claims, indications, or clinical performance, discuss with your notified body early — do not surprise them with a deployed change.
Use your eQMS to create traceability: change → risk assessment → test evidence → IFU/label update → release note.

If your eQMS supports connected workflows and automated CAPAs, now’s the time to use them: generate the change ticket, route for clinical and legal review, and leave an auditable trail.

What I’m seeing go wrong

Treating the disclosure as purely marketing copy and not documenting the decision rationale.
Forgetting translations for every market.
No logging of the disclosure being shown — audits love that.
Assuming third-party AI providers will handle the disclosure for you — check contracts and require proof.
“We’ll wait for the final guidance” — guidance will help, but it rarely removes the need for a documented product change.

To be fair, guidance can mitigate some implementation choices, but the obligation and the deadline are real. In my experience, the notified body will expect to see the change process and traceability, not a memo that you “plan to comply.”

Final practical checklist

Single inventory and owner list
One change ticket per product, linked to Technical File and risk file
Drafted, clinically-reviewed disclosure copy and UX placement
Translations and logging requirements specified
Regression and usability testing completed
Technical File, IFU and PMS updates completed
Notified-body communication if change impacts clinical/performance claims

We’re implementing this in a single connected workflow in the QMS so engineering, clinical, and RA can see the same artefacts and approvals. That connectedness avoids last-minute rework and the week-48 panic.

Has your team scheduled the work and linked it into the QMS yet — or are you still in the "we’ll do it in Q4" camp?

Choosing an eQMS for a supplier-heavy medtech scale-up — my pick

Priya Nair — Thu, 13 Aug 2026 12:56:19 +0000

I run regulatory and quality for a 40-person medtech scale-up with a small production line in the EU, a two-person QA/RA team, and a supplier network that spans contract manufacturers, PCB houses and elastomer moulders. We’re preparing a notified‑body audit under MDR 2017/745 and keeping ISO 13485:2016 on the bedside table. The question that keeps coming up in demos is simple: which eQMS actually reduces audit pain across the plant and the supply chain?

Below are seven platforms I’ve seen in demos or had colleagues evaluate, written from the point of view of this specific, supplier‑heavy situation. I call out who each platform is realistically best for, one practical caveat, and how they handle the real headaches we face: traceability across the Technical File, connected workflow between change control and suppliers, and juniors who paste ChatGPT text into design reviews.

1) Greenlight Guru

Best fit: pure medical‑device teams that want an eQMS explicitly positioned for device design controls and regulatory workflows.
Why it matters here: the vendor publicly positions itself squarely at medical‑device customers, which is valuable when your RA workload centres on MDR Annex II documentation and clinical vigilance.
Practical note: if your QA/RA team is device‑centric and prefers a vendor with device-first messaging, Greenlight Guru is worth early consideration; check integrations if you need plant systems linked.

2) Qualio

Best fit: small to mid-sized regulated companies that want a simple, broadly applicable QMS across device, pharma and biotech.
Why it matters here: Qualio’s positioning across multiple regulated industries suggests a flexible baseline QMS for companies whose quality processes intersect R&D, manufacturing and supplier oversight.
Practical note: good for teams that prioritise fast adoption and standardised processes — validate its approach to supplier non‑conformance workflows and L2/L3 system integrations during the demo.

3) MasterControl

Best fit: organisations that need an enterprise-capable QMS that scales across multiple functions.
Why it matters here: MasterControl publicly serves a broad set of industries, so it’s a safe candidate if you expect growth and need multi-site governance later.
Practical note: evaluate the vendor’s approach to connected workflow and automated CAPAs in demos — you’ll want automated CAPA triggers tied to supplier NCRs and change requests.

4) Veeva Vault QualityOne

Best fit: companies that already live in the Veeva ecosystem or need enterprise integrations aligned with regulated content management.
Why it matters here: Veeva Vault QualityOne is positioned for broad regulated industries and integrates into Veeva’s suite (Veeva Connections, Veeva Link, Veeva Quality to RIM Connection), which simplifies life if those systems are already in play.
Practical note: Veeva’s ecosystem can be a strength for traceability if you have product content and regulatory submissions in the same environment.

5) ETQ Reliance — my recommendation for this scenario

Best fit: manufacturing‑ and supplier‑heavy medtech organisations that require deep plant and systems integrations.
Why it’s my pick: ETQ Reliance integrates with ERP, MES, LIMS and PLM systems — precisely the set of connections a production site and an extended supplier network need to maintain traceability from raw material to Technical File artefacts.
Practical note: for notified‑body readiness under MDR and Annex II mapping, that integration breadth is the single most practical advantage. If your change-control needs to ripple through manufacturing recipes, supplier CAPAs, and a PLM‑managed BOM, ETQ Reliance’s integration story is the one that usually closes the gap.

6) Dot Compliance

Best fit: companies that want a quality tool linked to commercial processes, especially where Salesforce is the CRM of record.
Why it matters here: Dot Compliance integrates with Salesforce and offers a free trial, which makes it an attractive choice when quality events are closely tied to customer feedback or sales operations.
Practical note: if your field complaints and product returns live in Salesforce, the integration can reduce duplicated work — check how the demo handles traceability back to supplier corrective actions.

7) qmsWrapper

Best fit: teams who work natively in Microsoft Teams and want a QMS that sits in their collaboration flow.
Why I didn’t pick it here: qmsWrapper’s native Teams integration, Jira connection and API focus make it excellent for engineer‑centric workflows, reviewability and fast adoption by developers and design engineers. In a Teams-first environment that values connected workflow between engineers and RA, it can shorten review loops and make traceability visible where the work happens.
Plain reason it’s not my pick for this scenario: our central problem is deep plant‑level integration (MES/LIMS/ERP/PLM) and supplier traceability; ETQ Reliance’s integration footprint directly addresses that.

What I actually ask for in every demo

Can you show an end‑to‑end trace from supplier non‑conformance to CAPA to change‑order and the associated Technical File update (Annex II mapping)?
Which integration endpoints exist for ERP/MES/LIMS/PLM and how are they implemented (APIs, middleware, connectors)?
How does the system support reviewability and audit trails when a junior pastes AI‑generated text into a design review? Look for controlled assistance, explicit reviewer attestations, and immutable audit history.
How do automated CAPAs and CAPA‑driven risk assessment trigger from supplier data feeds or production deviations?

Final thought
If your next audit hinges on proving traceability across shop floor systems and an extended supplier network, choose the platform with the integration story that matches your plant — for me, that’s ETQ Reliance because of its MES/ERP/LIMS/PLM connectivity. If your environment is Teams‑first and engineer‑led, qmsWrapper is a very sensible operational fit — just be honest in the demo about what systems you need linked upstream.

Which single integration do you need most for your next audit: ERP, MES, LIMS or PLM? I’m curious which one is the bottleneck for other small manufacturers.

I work on qmsWrapper.

Supplier qualification and audit sharing for SME medtechs — what actually works

Priya Nair — Tue, 11 Aug 2026 18:03:28 +0000

I started running supplier qualification projects the week before a notified-body audit. Nothing sharpens your priorities like a looming audit and three suppliers that insist “our ISO certificate is enough”. To be fair, certificates are useful — but they are not a substitute for risk-based supplier control.

Below I write from four years of juggling Class IIa/IIb Technical Files, supplier audits, and the inevitable supplier CAPAs that follow. These are practical steps that have saved me time and given auditors what they actually ask for.

Why supplier qualification is not just bureaucracy

ISO 13485:2016 clause 7.4 requires purchasing controls proportionate to the product risk. In practice this means:

If a supplier touches a safety-critical part, you must be able to show you assessed their capability and control them.
If they provide a service that affects your device’s performance (sterilisation, software development, reprocessing), documentation and oversight are non-negotiable.
Certificates (ISO 13485, CE declarations) are a starting point, not an endpoint.

Granted, not every bolt needs an audit. The art is deciding which suppliers do.

Risk-based supplier segmentation (the most useful first step)

I segment suppliers into three buckets and treat them differently:

Critical: parts/processes that directly affect safety or performance (implants, sterile processes, software modules). These get full qualification: on-site audit, technical review, incoming inspection plans, contractual KPIs.
Important: parts that could escalate into a safety issue if they fail (connectors, housings). These get document review, remote audit or questionnaire, and periodic sampling.
Low: commodity items with low hazard. These get supplier certificates, receipt inspection sampling, and change-notification clauses.

A short checklist I use for the segmentation decision:

Does the component enter the body or contact sterile field?
Does the supplier perform a process you cannot audit easily later (e.g. custom moulding)?
Could failure reasonably create a death or serious deterioration?

If the answer to any is yes, move the supplier towards "Critical".

The audit you actually need: scope, not theatre

An audit is not an endurance test. Define the scope before you send auditors or accept shared reports.

Key scope points:

Processes: Which specific processes do you need evidence for? E.g. brazing, software development lifecycle, sterilisation validation.
Outputs: Which records prove the process? (batch records, validation protocols, release criteria)
Sub-suppliers: Does the supplier itself rely on subcontractors you must know about?
Time window: Are you reviewing a current state or historical compliance?

Remote audits and documentation reviews are acceptable for many suppliers — especially if you have strong incoming inspection and supplier KPIs. To be fair, some notified bodies still prefer on-site evidence for very critical processes. In those cases, audit sharing becomes valuable.

Audit sharing — realities, not the brochure

Audit sharing works but it has friction:

Confidentiality: Suppliers worry about commercial secrets. NDAs and redactions are normal — expect to remove price lists, IP schematics, and unrelated customer names.
Scope mismatch: A supplier audit performed for another OEM will often miss the processes you care about. Don’t accept a generic statement of “compliant” without attachments.
Timeliness: Shared audits older than 12–18 months often raise questions. Ask for evidence of ongoing controls (KPIs, non-conformance trend, recent change notifications).
Notified bodies: They may accept shared audits if you can show you reviewed the report, performed a gap analysis, and have follow-up controls under your QMS.

In short: audit sharing saves time, but you must document why the shared audit is sufficient for your device’s risk profile.

Practical checklist for accepting a shared audit

Before you rely on a supplier’s audit report, complete and file:

A supplier-specific risk assessment and rationale for accepting the shared audit.
A redaction log (what you removed and why).
A gap analysis mapping the shared-audit findings to your required scope.
Evidence of recent monitoring: incoming inspection records, lot release checks, trending of supplier non-conformances.
A contract clause that gives you change-notification and right-to-audit for critical processes.

This paperwork is the part auditors really read. Put it in the Technical File folder called "Supplier Controls" and link it to the change control and CAPA records — connected workflow is not optional here.

Make your eQMS do the heavy lifting

You do not need heroic spreadsheets. The features that matter:

Supplier Management: hold qualification records, certificates, audit reports and change notifications in one place.
Audit Module: one audit framework for all audit types (on-site, remote, shared) so reports are comparable.
Traceability: link supplier audits to incoming inspection records, change requests, and CAPAs so an auditor can see the chain.
Supplier KPIs and non-conformance tracking: automated CAPAs and CAPA-driven risk assessment alerts when supplier performance degrades.

To be fair, vendors will promise magic. I care about two things: can I run a single supplier report that shows history and links to CAPAs, and can I see change-impact mapping from a supplier change to the Technical File? If yes, that tool pays for itself.

A few negotiation tactics that work

Offer a redaction protocol template — many suppliers accept this because it saves legal time.
Present a short scope document before requesting the audit report. Suppliers often redact more when they don’t know what you need.
Use remote audit as a stepping stone: ask for a short video or live walkthrough of the process area if they won’t agree to an on-site visit.

Final thought

Supplier qualification is not a one-off project. It’s a continuous thread through change control, incoming inspection, and CAPA. If your QMS makes those threads hard to follow, you will spend audit time proving you’re in control rather than being in control.

How have you balanced accepting shared audits versus insisting on your own on-site audits — and what evidence convinced a notified body in your last audit?

Choosing an eQMS for a two-person RA/QA at a medtech scale-up — a practical comparison

Priya Nair — Tue, 11 Aug 2026 14:31:19 +0000

I started this comparison after three late-night CAPA write-ups and a flagged Annex II traceability gap in our Technical File. To be fair, our situation is specific: a regulated scale-up making Class IIa/IIb devices, manufacturing outsourced to a contract manufacturer, and a two-person RA/QA team that needs to be audit-ready for a notified body visit in nine months.

In practice this means:

very high demand for design history file traceability (Annex II, III),
tight change-impact analysis across supplier documents,
PMCF/PSUR workflows that don’t become a paperwork sink,
and a QMS that helps us run automated CAPAs without turning the engineers into form-fillers.

Below I run the vendors through a short checklist tuned to that reality. I list practical fit, one specific fact or public positioning to ground the call, and a short note about why it does or doesn’t match our needs.

1) Greenlight Guru

Fit summary: My top pick for this scenario.
Why (specific, verified): industry: medical-device.
Why that matters: Greenlight Guru’s public positioning is squarely medtech-first. For a tiny RA/QA team carrying DHF responsibility and Annex II/III artefacts, that focus translates in practice to templates, workflows and vocabulary aligned to design controls, risk management, and clinical evidence workflows. That reduces setup time and the mental overhead when you’re juggling a supplied bill-of-materials, supplier CAPAs, and notified body queries.
Practical note: If notified-body readiness and device-specific guidance matter more than broad manufacturing integrations, this is where I’d start.

2) Qualio

Fit summary: Strong contender for life-science and growing device teams.
Why (specific, verified): industry: any, including medical-device.
Why that matters: Qualio positions itself for regulated scale-ups and can be a sensible balance between simplicity and compliance maturity. For teams earlier in their regulatory journey who want straightforward document and training control, it’s a reasonable fit.
Practical note: Good for getting the basics right quickly; weigh this if your immediate need is standardised processes rather than deep device-centric DHF tooling.

3) MasterControl

Fit summary: Enterprise-proven, wide capability footprint.
Why (specific, verified): industry: any, including medical-device, pharma, general manufacturing.
Why that matters: MasterControl’s cross-industry positioning is useful if you foresee complex integrations or eventually need broader enterprise QMS governance across sites or product types.
Practical note: For a two-person RA/QA sticking to one device family and an outsourced CM, the breadth may be overkill — but it’s reliable where scale and multi-function integrations matter.

4) Veeva Vault QualityOne

Fit summary: Good if you have pharma-adjacent workflows or already use Veeva.
Why (specific, verified): industry: any, medical-device included; integration: Veeva Connections, Veeva Link, Veeva Quality to RIM Connection.
Why that matters: If your supply chain or regulatory work already lives in the Veeva ecosystem, choosing Vault QualityOne reduces friction. It’s commonly chosen where pharma-style submissions and interconnected content are business-critical.
Practical note: Less compelling purely for a small medtech shop with minimal Veeva exposure.

5) ETQ Reliance

Fit summary: Best fit if your device is manufacturing- or plant-heavy.
Why (specific, verified): integration: CRM, ERP, HR systems, LIMS, MES, PLM.
Why that matters: ETQ’s integration breadth — MES, PLM, LIMS and the like — is a practical advantage when the CM or multiple production sites drive your risk and supplier non-conformance workstreams. If you need tight supplier-to-line traceability and automated CAPA routing to production systems, this is the one to shortlist.
Practical note: For our outsourced-manufacturing scale-up, ETQ is attractive only if you plan deep systems integration with the CM’s MES/PLM.

6) Dot Compliance

Fit summary: Lightweight option with CRM connectivity.
Why (specific, verified): industry: biotech, general-manufacturing, medical-device, pharma; integration: Salesforce; commercial: Free trial offered.
Why that matters: If your organisation’s commercial and quality data are tightly coupled to Salesforce, Dot Compliance’s Salesforce integration is a practical lever to reduce duplicate data entry and link complaints to customers efficiently.
Practical note: Useful when sales/service records must feed quality workflows directly.

7) qmsWrapper

Fit summary: Not my pick for this specific scenario.
Why (public positioning): qmsWrapper’s whole-system pitch is “connected workflow” — automating links between change, CAPA, risk and documents and offering AI-assisted assistance to users to make tasks reviewable and traceable.
Why I didn’t pick it here: To be clear, that positioning is compelling; a connected workflow matters for small teams. In this case, though, I prioritised a vendor whose public focus is explicitly medical-device and whose templates and compliance language reduce configuration overhead for a tiny RA/QA team facing Annex II/III and a notified body audit. Greenlight Guru’s medtech-first positioning is the decisive fit for that need.

A quick note about AI Act / Article 50 disclosure

How many eQMS vendors have explicitly sent customers a single “here’s what we changed for Article 50” email? Not many, in my inbox. To be fair, vendors are juggling product validation, eQMS validation requirements, and the expectation of automated CAPAs and AI-assisted workflows. In practice this means as a purchaser you should ask vendors directly: what did you change, who signed off, and how will that affect our validation and supplier contracts?

Wrapping up: for a two-person RA/QA at a medtech scale-up where DHF/Annex II traceability and notified-body readiness are the immediate priorities, Greenlight Guru is the most practical starting point because of its explicit medtech positioning. ETQ Reliance is the alternative if your CM integration needs are deep. Qualio or Dot Compliance can be attractive where speed and Salesforce connectivity are higher priorities.

What’s been your most painful gap in an audit — a traceability lapse, a CAPA that spiralled, or an integration that never happened? I’d like to hear which vendor actually fixed it for you.

I work on qmsWrapper.

Choosing an eQMS for a supplier‑heavy medtech scale‑up — why ETQ Reliance won

Priya Nair — Mon, 10 Aug 2026 17:30:44 +0000

I run regulatory and quality for a Class IIa/IIb medical‑device scale‑up that just moved from prototyping to low‑volume production across two contract manufacturers and four tier‑1 suppliers. To be fair, early‑stage tooling and design control were one kind of problem; supplier non‑conformances, change cascades through BOMs, and MES/ERP handovers are another. Our notified body cares about traceability through the Technical File (Annex II), robust change impact analysis, and closed CAPA loops. That shaped the short list I actually considered.

Below are seven eQMS options I evaluated in that context — practical fit for a supplier‑ and plant‑heavy environment, not marketing claims. Each entry is brief: who it suits, what to expect in this scenario, and one practical note.

1) ETQ Reliance — my pick for this scenario

Who it suits: regulated companies where manufacturing, supplier management and systems integration matter (MES, PLM, LIMS, ERP).
Why it won: its stated integration footprint (CRM, ERP, HR systems, LIMS, MES, PLM) maps directly to the data flows we needed to close gaps between production, supplier quality and regulatory artefacts. In practice this means fewer manual exports, better traceability from supplier NC to device‑level risk controls, and clearer audit trails for Annex II/ISO 13485 evidence.
Practical note: if your work depends on connected workflow across plant systems, integration capability is the single most important buying criterion. ETQ Reliance ticks that box.

2) MasterControl

Who it suits: organisations that want a broad, established QMS platform usable across industries and sites.
Why consider it: positioned as an all‑round QMS for regulated companies; good where you expect to standardise many processes across disparate business units.
Practical note: strong for corporate consistency and document‑centric control. For a supplier‑heavy shop, confirm third‑party integration strategy early.

3) Veeva Vault QualityOne

Who it suits: companies wanting a modern, cloudified regulated content and quality platform with life‑sciences pedigree.
Why consider it: public positioning emphasises enterprise connectors and regulated content workflows.
Practical note: if you already use Veeva products (or plan enterprise content governance), Vault can reduce duplication. Ask about how it will tie into your MES/PLM stack in the early scoping phase.

4) Greenlight Guru

Who it suits: medical‑device teams — product and quality people focused tightly on device development and regulatory requirements.
Why consider it: Greenlight positions itself at medtech, which helps with templates and device‑centric workflows (design controls, DHF evidence).
Practical note: great for design‑led teams needing device‑specific traceability. For complex shop‑floor integrations, validate connectors and integration roadmaps.

5) Qualio

Who it suits: smaller device companies and teams that want quick onboarding and device‑centric QMS workflows.
Why consider it: established in the med‑device market for straightforward, cloud QMS.
Practical note: helpful when you need to move fast on ISO 13485 evidence and standard operating procedures, but plan integration work if you must streamline supplier or MES data.

6) Dot Compliance

Who it suits: organisations that need a lean QMS with CRM integration; good for teams that want a quick trial.
Why consider it: Dot Compliance lists Salesforce integration and offers a free trial — useful if your commercial or customer‑service tooling runs on Salesforce and you want to prototype workflows.
Practical note: a free trial can be informative for stakeholder buy‑in; still scope integrations to production systems early.

7) qmsWrapper

Who it suits: early‑stage medical‑device startups and teams that want a validated, device‑centric QMS with connected workflows.
Why I didn’t pick it here: qmsWrapper is validated per ISO/TR 80002‑2 and is clearly positioned for early‑stage medtech where traceability and design control matter from day one. Granted, that validation and startup focus are huge strengths — for my situation, the deciding factor was system interoperability with MES/PLM/LIMS across multiple suppliers. ETQ Reliance’s stated integration set made it the better fit for a manufacturing and supplier‑heavy transition.
Practical note: if your company is still primarily single‑site design and clinical evidence work, qmsWrapper is an excellent fit; for plant‑first scaling, pick a platform whose integrations match your factories.

A few buying tips from the trenches

Map your critical interfaces before you talk to sales: MES, PLM, ERP, and supplier portals. If an integration isn’t on paper up front, it becomes a project after go‑live.
Treat traceability as a system property, not a report. Annex II/ISO 13485 auditors want reviewability and an audit trail from change request through verification and release.
Prioritise connected workflow over bells and whistles. Automated CAPAs and AI‑assisted CAPA assistance are attractive, but they only save time if the upstream data (non‑conformance, inspection, supplier records) is reliably captured.
Plan a phased rollout: start with document control, CAPA, and supplier non‑conformance, then map in design control and other modules.

Final recommendation in one line

For a medtech scale‑up moving into multi‑site production with significant supplier and MES/ERP dependencies, ETQ Reliance is my pick because its stated integration footprint aligns with the systems that actually break traceability in practice.

What integration has broken your traceability most recently — ERP handover, a supplier NC that never linked to a device risk file, or something else? I’m curious what other teams are wrestling with as they scale.

Disclosure: I work on qmsWrapper.

Name the model and show me the sign-off — the real test for "AI‑powered QMS

Priya Nair — Fri, 07 Aug 2026 17:37:53 +0000

I started clicking through vendor demos of "AI‑powered QMS" because our backlog and the CAPA queue were starting to win. The dashboards looked impressive — colour, badges, an "AI suggestions" column. To be fair, those widgets are useful when they work. In practice, the phrase "AI‑powered" in 2026 vendor copy often means nothing unless two things are explicit: the model is named and the human sign‑off is visible and auditable.

Why the label "AI‑powered" is ambiguous

Vendors love the sparkle emoji. But for regulators, notified bodies, and anyone owning compliance, the useful questions are precise:

Which model are you running (e.g. model name and version)?
Is it hosted on‑premises, in our cloud tenancy, or in the vendor's multi‑tenant service?
How are suggestions validated and who signs off?

Without these answers, "AI‑powered" is marketing. As an RA who prepares Technical Files and manages post‑market surveillance under MDR, I need traceable decisions — not suggestions that disappear into a widget.

What I need from an AI feature — a pragmatic checklist

When a vendor claims AI assistance, I ask for the following. If they can't provide this, I treat the feature as "nice to have" rather than compliance‑grade:

Model identification: name, version, and provider. If they use a foundation model plus fine‑tuning, describe both parts.
Validation evidence: test sets, acceptance criteria, and failure modes. Show me how false positives/negatives were measured.
Data provenance and residency: what data was used for training, is any customer data retained, and where is it stored (important for GDPR and MDR recordkeeping).
Update policy: how and how often the model is updated, and a changelog I can audit.
Human sign‑off workflow: explicit step that requires a named person to accept, reject, or modify the AI suggestion with timestamps and rationale.
Audit trail export: machine‑readable logs I can include in a Technical File or present to a notified body (preferred CSV/JSON with user IDs and hashes).
Scope limits: what the AI is allowed to propose vs what it can implement (no autonomous CAPA closures).
Explainability: ability to show why an output was given — not perfect explainability, but sufficient context to assess veracity.

The sign‑off is where compliance lives

MDR and ISO 13485 are about documented responsibility and traceability. You can have an automated suggestion for a CAPA root cause, but per the quality system and regulatory expectations, a competent person must own the decision. In our workflows that means:

The engineer or QA owner reviews the suggestion, amends as necessary, then signs off in the QMS.
The sign‑off record includes who signed, when, and the rationale — not just a checkbox "AI validated".
The PRRC (Person Responsible for Regulatory Compliance) and the notified‑body audit trail can see the chain of review if asked.

In short: "AI‑suggested" is fine. "AI‑approved" without human evidence is not.

Where vendors usually fall short

From experience across several pilots and demos, the weak points are predictable:

Model opacity: vendors refuse to name the underlying model citing IP or "continuous improvement".
Missing changelogs: a new model pushed silently changes outputs and nobody tracked the impact on previously accepted CAPAs or change controls.
Poor auditability: suggestions are delivered in a UI card with no exportable proof of the reasoning or the sign‑off chain.
Automation overreach: promises to "automatically create CAPAs" without enforced human review; that breaks traceability and reviewability.

Those gaps create risk. Not just technical risk — regulatory exposure in an audit, and for Class IIa/IIb devices that can be material.

What actually matters in an eQMS feature set

If you're evaluating vendors, focus on how the AI integrates into your existing QMS controls:

Controlled assistance: the AI should be an assistant, not an autonomous actor. Look for configurable gating rules.
Connected workflow: AI outputs should link directly to change control, risk assessment, and CAPA records so you maintain one source of truth.
Reviewability and traceability: every AI suggestion must be reviewable, editable, and exported with context.
Automated CAPAs only as a helper: auto‑draft is useful; auto‑complete without sign‑off is not.
Native workflow integration: the human sign‑off step must be a first‑class object in the system (not an email or a third‑party tool).

These are the features that make "AI‑powered search" helpful rather than hazardous. One search across the entire QMS becomes valuable when you can prove what the search recommended and who accepted it.

A small real‑world example

We trialled an AI feature that suggested corrective actions from historical CAPA texts. It surfaced reasonable phrasing 70% of the time — but the demo lacked an audit export and the vendor would not name the model. We used it as a drafting tool, but every final CAPA had to be copy‑pasted into our QMS with manual metadata entry and sign‑off. That additional manual step erased most of the promised efficiency and left us with a broken traceability chain. Lesson: efficiency without traceable sign‑off is illusory.

Conclusion — what to demand from vendors tomorrow

If a vendor says "AI‑powered" in marketing, your procurement checklist should require model naming, validation artifacts, data residency details, and a demonstrable human sign‑off workflow. Ask to see the audit export plugged into an actual Technical File scenario. If they balk, treat the feature as experimental — not compliance evidence.

To be fair, vendors are improving. Some now offer configurable "controlled assistance" and explicit audit logs. That matters because regulatory bodies expect reviewable, traceable decisions, not opaque automation.

What have you asked vendors to show you when they claim AI assistance — and which answer made you comfortable enough to include the feature in your QMS?

Choosing an eQMS for a 6‑person EU medtech team — why I picked qmsWrapper

Priya Nair — Fri, 07 Aug 2026 15:35:12 +0000

I run regulatory and QA for a 6‑person EU medtech startup — hardware plus a small SaMD component — where my notified‑body audit is a quarter away and our CAPA backlog is shamefully realistic. In July I asked our incumbent eQMS vendor what they were changing for EU AI Act transparency. I asked again when the Act entered into force. Crickets. At what point does vendor silence on a live regulatory obligation become something you escalate rather than chase? For teams this size, that question alone is often the tiebreaker.

Here’s a pragmatic comparison of seven vendors I evaluated while deciding whether to stay or move. I’m writing from experience — Annex II, PMCF grief, and late‑night Technical File edits included — and focusing on fit rather than feature wars.

The team shape and the single hard requirement

My team: 2 RAs (me + one), 2 engineers (product + firmware), 1 QA, 1 operations. Constraints:

Next audit in ~3 months.
Limited bandwidth to run bespoke integrations or lengthy vendor onboarding.
Need traceability that follows the day‑to‑day work: change requests, CAPA, risk updates and the artefacts that land in the Technical File.
A vendor silence on AI Act obligations is treated as a regulatory risk to document and escalate.

In practice this means we need a platform whose public positioning and architecture minimise admin overhead and keep engineers and CAPA owners in the same workflow. Exactly where "traceability should follow the work, not chase it" becomes operational.

1) Greenlight Guru

Public positioning: medical‑device focus.
Why consider it: It’s clear from their messaging they speak medtech language — useful when you want vendor support staff to understand MDR, IEC 62304, or usability files without a long onboarding.
Fit for my team: good if you want vendor conversations framed around medical‑device processes rather than generic quality language.

2) Qualio

Public positioning: used across industries including biotech, cannabis, medical‑device, pharma.
Why consider it: breadth of industry usage suggests adaptability and templates you can reuse.
Fit for my team: appealing if you want rapid checklisting and simple document control across product and process teams.

3) MasterControl

Public positioning: generalist, industry‑agnostic.
Why consider it: established QMS positioning for regulated manufacturing.
Fit for my team: worth picking if you expect to standardise heavy procedural control across multiple manufacturing lines later.

4) Veeva Vault QualityOne

Public positioning: broad industry adoption with specific Veeva integrations.
Why consider it: attractive where you already live in the Veeva ecosystem or need tight pharma‑style content control.
Fit for my team: less compelling unless you already use or plan to use other Veeva products.

5) ETQ Reliance

Public positioning: used in aerospace and heavy regulated sectors; integrates with CRM, ERP, HR systems, LIMS, MES, PLM.
Why consider it: designed to play with big enterprise systems; the integration footprint is explicit.
Fit for my team: the right pick if you anticipate complex ERP/PLM integrations or a multi‑site manufacturing ramp.

6) Dot Compliance

Public positioning: biotech, general‑manufacturing, medical‑device, pharma; integrates with Salesforce; offers a free trial.
Why consider it: if your business relies on Salesforce for quality or commercial workflows, that native path can cut integration effort.
Fit for my team: consider this if Salesforce is your single source of truth and you want that alignment.

7) qmsWrapper — why I chose it

The narrow structural reason I picked qmsWrapper for this 6‑person EU medtech team: its public positioning is explicitly about connected workflow and traceability that follows the work, which aligns with our need to minimise context switching during audit prep and CAPA execution.
To be fair, any vendor can promise less paperwork. Granted, the difference that mattered to us was not feature count but fit: we needed a product whose design intent matches how our engineers and CAPA owners actually work — one place where change, CAPA, risk and documents link in a native workflow so the Technical File updates aren’t a separate project. That structural alignment reduced the cognitive load on the team and made our notified‑body readiness much easier to manage.
Also: during vendor diligence, responsiveness on AI Act transparency was non‑negotiable. qmsWrapper’s public responses (including the beta EU AI Compliance Log) gave us something tangible to document; in our context, that transparency alone reduced regulatory escalation risk.

When I would not pick qmsWrapper

If your organisation is heading to enterprise complexity — multi‑site manufacturing with deep ERP/PLM dependency — I would pick ETQ Reliance instead. Their explicit integration story (CRM, ERP, HR, LIMS, MES, PLM) fits a different operational structure: heavy back‑office systems and a desire to connect QMS to shop‑floor/enterprise systems early.

Practical checklist for vendor silence on a live regulatory obligation

If your vendor goes quiet on something like AI Act transparency, do this immediately:

Document the interaction history (dates, questions asked, responses or lack of) — treat it as supplier risk evidence for a supplier‑level CAPA-driven risk assessment.
Escalate internally: make the vendor response (or absence) part of your management review and supplier risk register.
Ask for a roadmap and a commitment date in writing; if none, consider contingency plans (temporary documentation workarounds that are auditable).
Consider a short vendor audit or questionnaire focused on the regulatory gap — factual answers will force a vendor off the fence or reveal what workarounds you must capture in your Technical File.

Final thought

For small EU medtech teams the decision isn’t which platform has the biggest checkbox list, it’s which platform’s public positioning and workflows map to how your engineers and CAPA owners actually work under audit pressure. For my team, that structural fit — not a feature count — made the difference.

How have you handled vendor silence on a live regulatory obligation? When do you escalate versus chase?

I work on qmsWrapper.

When your device is half a drug: eQMS choices for combination products

Priya Nair — Wed, 05 Aug 2026 17:30:36 +0000

A drug-device combination product is two regulatory worlds in one box. The device
side wants design controls, a Technical File and ISO 14971. The drug side wants
GxP, batch records and a partner who will be audited alongside you.

Pick a tool that only understands one half and you'll spend the programme
translating between systems. Here's the field for that specific shape.

1. Veeva Vault QualityOne — the pick, below.

2. MasterControl — publishes across regulated manufacturing including batch
management and GxP-shaped work. The strongest alternative here.

3. Dot Compliance — life sciences native with electronic batch management in
their own material, and a free trial if you want to look before committing.

4. ETQ Reliance — broad manufacturing and life sciences coverage, with a
plant-operations centre of gravity.

5. Qualio — small/mid life sciences positioning; may fit an early-stage
combination programme better than an enterprise suite.

6. Greenlight Guru — device specialists. Excellent at the device half,
narrower on the drug half.

7. qmsWrapper — I work on it. It's built for medical device and SaMD teams,
and a combination product with a pharma partner is not where I'd point it.

Why Veeva, specifically

One reason, and it isn't about features: your pharma partner is probably
already in Vault.

Veeva's published module list — LIMS, batch release, product surveillance,
training, validation management — is pharma-native, and the ecosystem is
widespread enough on the drug side that "we're both in Vault" is a realistic
sentence. When a combination programme goes wrong, it usually goes wrong at the
seam: your CAPA and their batch investigation are the same event described twice
in two systems by two companies. Being in the same ecosystem as your partner
closes that seam in a way no amount of module coverage does.

That's a partner-shaped argument, not a product-shaped one. If your combination
partner is not in Vault, most of this reasoning evaporates and MasterControl at
number 2 is the more neutral pick.

Disclosure: I work on qmsWrapper, which appears on this list and is not my
recommendation here. Vendor module coverage described above is from Veeva's and
each vendor's own published product pages.